Translarna

William Blair Upgrades PTC Therapeutics On Risdiplam Prospects

Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna

A Timeline Of PTC Therapeutics' Translarna Journey

Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna

A Timeline Of PTC Therapeutics' Translarna Journey

PTC Therapeutics Surges 88% On European Marketing Authorization

PTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval

PTC Therapeutics Surges 88% On European Marketing Authorization

PTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval

Need For New Drug Trial Increases Long-Term Risk For PTC Therapeutics, Says Wedbush

Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares

Translarna Recent News

Wall Street Really Blew It On PTC Therapeutics

PTC Therapeutics: Oppenheimer Bull Cuts Target From $111 To $39; Jefferies Less Certain on Translarna

Roth Capital On PTC Therapeutics: 'Staying On The Sidelines' Until Regulatory Clarity

PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts